Institute Clinic of Gynecology

Barcelona, Spain

Institute Clinic of Gynecology

Barcelona, Spain
SEARCH FILTERS
Time filter
Source Type

Luque A.,Lhospitalet Of Llobregat | Farwati A.,Lhospitalet Of Llobregat | Crovetto F.,Institute Clinic of Gynecology | Crovetto F.,University of Milan | And 4 more authors.
Scientific Reports | Year: 2014

To assess the usefulness of circulating microRNAs (miRNAs) as non-invasive molecular biomarkers for early prediction of preeclampsia, a differential miRNA profiling analysis was performed in first-trimester pooled sera from 31 early preeclampsia patients, requiring delivery before 34 weeks of gestation, and 44 uncomplicated pregnancies using microfluidic arrays. Among a total of 754 miRNAs analyzed, the presence of 63 miRNAs (8%) was consistently documented in the sera from preeclampsia and control samples. Nevertheless, only 15 amplified miRNAs (2%) seemed to be differentially, although modestly, represented (fold change range: 0.4-1.4). After stem loop RT-qPCR from individual samples, the statistical analysis confirmed that none of the most consistent and differentially represented miRNAs (3 overrepresented and 4 underrepresented) were differentially abundant in serum from preeclamptic pregnancies compared with serum from normal pregnancies. Therefore, maternal serum miRNA assessment at first-trimester of pregnancy does not appear to have any predictive value for early preeclampsia.


Martinez-Serrano M.J.,Institute Clinic of Gynecology | Caballero-Banos M.,University of Barcelona | Vilella R.,University of Barcelona | Vidal L.,University of Barcelona | And 2 more authors.
International Journal of Gynecological Cancer | Year: 2015

Objective: Current evidence suggests that the presence of tumor-initiating cells (TICs) in epithelial ovarian cancer (EOC) has a role in chemoresistance and relapse. Surface markers such as CD44+/CD24-, CD117+, and CD133+ expression have been reported as potential markers for TICs related to ovarian cancer and tumorigenic cell lines. In this study, we have investigated if spheroid forms are TIC specific or whether they can also be produced by somatic stem cells from healthy tissue in vitro. In addition, we also investigated the specificity of surface markers to identify TICs from papillary serous EOC patients. Methods: Cells were obtained from fresh tumors from 10 chemotherapy-naive patients with EOC, and cells from ovarian and tubal epithelium were obtained from 5 healthy menopausal women undergoing surgery for benign pathology and cultured in standard and in selective medium. Cells forming nonadherent spheroids were considered TICs, and the adherent cells were considered as nonYTIC-like. Percentages of CD24+, CD44+, CD117+, CD133+, and vascular endothelial growth factor receptor (VEGF-R)+ cell surface markers were analyzed by flow cytometry. Results: Four of 10 EOC cell tissues were excluded from the study. Tumor cells cultured in selective medium developed spheroid forms after 1 to 7 weeks in 5 of 6 EOC patients. No spheroid forms were observed in cultures of cells from healthy women. Unlike previously published data, low levels of CD24+, CD44+, CD117+, and VEGF-R+ expression were observed in spheroid cells, whereas expression of CD133+ was moderate but higher in adherent cells from papillary serous EOC cells in comparison with adherent cells from controls. Conclusions: Papillary serous EOC contains TICs that formspheroids with lowexpression of CD44+, CD24+, CD117+ and VEGF-R+. Further research is required to find specific surface markers to identify papillary serous TICs. Copyright © 2014 by IGCS and ESGO.

Loading Institute Clinic of Gynecology collaborators
Loading Institute Clinic of Gynecology collaborators